Purpose After approval of anti-programmed cell death (PD)-1 antibodies, treatment for non-small
cell lung cancer (NSCLC) has drastically changed. However, even in patients with …

The current coronavirus disease 2019 (COVID‐19) pandemic is associated with a heavy
burden on the mental and physical health of patients, regional healthcare resources, and global …

Aim: To evaluate the efficacy and safety of re-treatment with anti-programmed death (PD)-L1
antibody (atezolizumab) after anti-PD-1 antibody (nivolumab/pembrolizumab) treatment in …

A 65‐year‐old man with chronic progressive pulmonary aspergillosis (CPPA) was admitted
for the treatment of lung adenocarcinoma while receiving an immune checkpoint inhibitor, …

Background This study evaluated the efficacy and safety of retreatment with anti‐programmed
death 1 (anti‐PD‐1) antibodies in patients with advanced non‐small cell lung cancer (…

Although it ameliorates lung cancer, immunotherapy with immune checkpoint inhibitors (ICIs)
presents complications of infectious diseases, including tuberculosis. Incidence of …

In advanced lung cancer treatment, immunotherapy provides durable responses in some
patients. However, other patients experience progressive disease and the resistance …

Background Osimertinib is one of the standard first-line treatments for advanced non-small
cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations, because …

Recent advancements in cancer immunotherapy using immune checkpoint inhibitors (ICIs)
have received considerable attention. Although advantageous, ICI therapies cause unique …

Immunotherapy with immune checkpoint inhibitors (ICIs), while ameliorating lung cancer,
can cause infectious diseases, including tuberculosis, in addition to immune-related …